Cover Image
Market Research Report

DNA Diagnostics Market: Technology (Polymerase chain reaction, Microarrays, Lab-on-chip or biochips, In situ hybridization, Novel gene sequencing, Mass spectrometry), By Application -Forecast 2019-2024

Published by IndustryARC Product code 422154
Published Content info
Delivery time: 2-3 business days
Back to Top
DNA Diagnostics Market: Technology (Polymerase chain reaction, Microarrays, Lab-on-chip or biochips, In situ hybridization, Novel gene sequencing, Mass spectrometry), By Application -Forecast 2019-2024
Published: December 11, 2018 Content info:

DNA diagnostics is a pioneer technique which has modernized the field of medical diagnostics. Numerous disease causing genes are identified by understanding complete human genome. DNA based diagnostic tests help in the detection of mutations, disease causing genes, diagnosing monogenic disorders, etc. Various diseases, such as cancer, infectious diseases, and myogenic disorders etc. are easily identified and treated. The technique is majorly attributed to the quick rate of technological advances followed by development of strong methodologies such as polymerase chain reaction (PCR), microarrays, novel gene sequencing, sequencing technology, mass spectrometry and others. It is also used in prenatal diagnostics to determine mutations and genetic disorders and for clinical diagnosis. Pre-implantation diagnosis procedure by DNA diagnostic technique involves finding mutation in the 8 cell stage embryo before implantation.

Advancement in product design and technology has encouraged doctors and researchers to shift their focus from traditional diagnostic methods to novel technologies. Adoption of personalized medicines approach would positively influence the DNA diagnostics market in the near future. The optimization of sequencing technology can increase the market for DNA diagnostics.

This report identifies the DNA diagnostics market size in for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to DNA diagnostics market.

Geographic regions analyzed for DNA diagnostics market is divided into four sections i.e. North America, Europe, Asia Pacific and Rest of the World. An increased adoption of the DNA diagnostics technology, availability of infrastructure, growing awareness on timely diagnosis and possibility for more precise results are the driving factors for the market in North America and Europe. Asia Pacific is expected to show fastest growth in the future due to high funding by government in healthcare facilities that enable advancement in R and introduction of new technology.

This report identifies global DNA diagnostics market on the basis of technology, application and regional market as follows:

DNA diagnostics market is segmented based on technology include polymerase chain reaction (PCR), microarrays, lab-on-chip or biochips and in situ hybridization technologies are some of the major DNA diagnostics techniques available

Based on applications of DNA diagnostics - detection of mutations, disease causing genes, diagnosing monogenic disorders, etc.

This report is further segmented based on potential markets for DNA diagnostics. A detailed analysis by region - United States, Europe, Asia-Pacific (APAC) and Rest of the World (RoW), has been provided in this report.

This report looks into all the major companies operating in the DNA diagnostics market. Some of the major companies' profiles are as follows:

Roche Diagnostics

Bayer Diagnostic


Abbott laboratories

Gene-probe Inc.

Table of Contents

Table of Contents

1. DNA Diagnostics - Market Overview

2. Executive Summary

3. DNA Diagnostics - Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End User Profiling
    • 3.2.3. Top 5 Financials Analysis

4. DNA Diagnostics - Market Forces

  • 4.1. Drivers
    • 4.1.1. Increased adoption rate of DNA diagnostic testing techniques
  • 4.2. Restraints
  • 4.3. Opportunities
  • 4.4. Challenges
  • 4.5. Porter's Five Force Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Customers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. DNA Diagnostics Market - Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. DNA Diagnostics Market, By Technology Type

  • 6.1. Polymerase chain reaction (PCR)
  • 6.2. Microarrays
  • 6.3. Lab-on-chip or biochips
  • 6.4. In situ hybridization
  • 6.5. Novel gene sequencing
  • 6.6. Mass spectrometry

7. DNA Diagnostics Market, By application type

  • 7.1. Detection of mutations
  • 7.2. Detection of disease causing genes
  • 7.3. Diagnosing monogenic disorders
  • 7.4. Others

8. DNA Diagnostics Market, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. US
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. Europe
    • 8.3.1. U.K
    • 8.3.2. France
    • 8.3.3. Germany
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe
  • 8.4. Asia Pacific
    • 8.4.1. China
    • 8.4.2. South Korea
    • 8.4.3. Japan
    • 8.4.4. India
    • 8.4.5. Rest of Asia Pacific
  • 8.5. RoW

9. Market Entropy

  • 9.1. Expansion
  • 9.2. Technological Developments
  • 9.3. Merger & Acquisitions, and Joint Ventures
  • 9.4. Supply - Contract

10. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

  • 10.1. Roche Diagnostics
  • 10.2. Bayer Diagnostics
  • 10.3. Abbott Laboratories
  • 10.4. Sysmex.
  • 10.5. Gene-probe Inc.
  • 10.6. Bio-Rad Laboratories
  • 10.7. Illumina Inc.
  • 10.8. Johnson and Johnson
  • 10.9. Cepheid
  • 10.10. Novartis AG

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Expert Insights
Back to Top